Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Research Article

Effects of MCU-mediated Ca2+ Homeostasis on Ovarian Cancer Cell SKOV3 Proliferation, Migration and Transformation

Author(s): Lantao Zhao, Man Jiang, Tian Tian, Guanqun Wang, Yingying Mei, Guangming Fu and Na Zhou*

Volume 23, Issue 8, 2023

Published on: 26 August, 2022

Page: [774 - 783] Pages: 10

DOI: 10.2174/1566524022666220617143754

Price: $65

Abstract

Background: Atlas human proteomics database showed MCU as highly expressed in various tumor tissues, especially in ovarian cancer. Rare studies on the role of MCU and its regulation in ovarian cancer have been reported.

Objective: The objective of this study was to determine role of MCU in ovarian cancer cell SKOV3 proliferation, migration, and transformation, and explore the possible mechanism.

Methods: MCU siRNA on lentiviral particles were stably transfected into SKOV3 cells. CCK-8 assay was performed to analyze cell proliferation. Soft-agar colony formation assay was employed to evaluate tumorigenesis. Western blot and immunohistochemistry analyses were performed to evaluate the expression of MCU, MICU1 and phosphorylate of Akt in the ovarian cancer cell and tissue specimens. Scratch assay was combined with trans-well plates assay to detect the migration ability of cancer cells. The ROS production and Ca2+ expression were also determined.

Results: MCU expression was significantly higher in ovarian cancer tissues than normal tissues. MCU silencing decreased SKOV3 cell proliferation, migration, and transformation. ROS production was decreased after MCU silencing, depending on disturbed Ca2+ homeostasis. MICU1 expression has been found to be decreased and phosphorylation of Akt increased when MCU was silenced.

Conclusion: Down-regulation of MCU inhibited SKOV3 cell proliferation, migration, and transformation via disturbing Ca2+ homeostasis and decreasing ROS production. MICU1 and phosphorylation of Akt are associated with MCU-mediated ovarian cancer malignancy.

Keywords: MCU, Ca2+ homeostasis, ROS, SKOV3, ovarian cancer, proliferation, migration, transformation.

[1]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69(1): 7-34.
[http://dx.doi.org/10.3322/caac.21551] [PMID: 30620402]
[2]
Bamias A, Pignata S, Pujade-Lauraine E. Angiogenesis: A promising therapeutic target for ovarian cancer. Crit Rev Oncol Hematol 2012; 84(3): 314-26.
[http://dx.doi.org/10.1016/j.critrevonc.2012.04.002] [PMID: 22575381]
[3]
Zhou HY, Pon YL, Wong AS. HGF/MET signaling in ovarian cancer. Curr Mol Med 2008; 8(6): 469-80.
[http://dx.doi.org/10.2174/156652408785747933] [PMID: 18781954]
[4]
Dziegielewska B, Casarez EV, Yang WZ, Gray LS, Dziegielewski J, Slack-Davis JK. T-Type Ca2+ channel inhibition sensitizes ovarian cancer to carboplatin. Mol Cancer Ther 2016; 15(3): 460-70.
[http://dx.doi.org/10.1158/1535-7163.MCT-15-0456] [PMID: 26832797]
[5]
Yu Y, Xie Q, Liu W, et al. Increased intracellular Ca2+ decreases cisplatin resistance by regulating iNOS expression in human ovarian cancer cells. Biomed Pharmacother 2017; 86: 8-15.
[http://dx.doi.org/10.1016/j.biopha.2016.11.135] [PMID: 27936394]
[6]
Xu L, Xie Q, Qi L, et al. Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells. Oncol Rep 2018; 39(3): 985-92.
[PMID: 29286126]
[7]
Xie Q, Su J, Jiao B, et al. ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells. Int J Oncol 2016; 49(6): 2507-19.
[http://dx.doi.org/10.3892/ijo.2016.3733] [PMID: 27748803]
[8]
Marchi S, Vitto VA, Danese A, Wieckowski MR, Giorgi C, Pinton P. Mitochondrial calcium uniporter complex modulation in cancerogenesis. Cell Cycle 2019; 18(10): 1068-83.
[http://dx.doi.org/10.1080/15384101.2019.1612698] [PMID: 31032692]
[9]
Zhao L, Li S, Wang S, Yu N, Liu J. The effect of mitochondrial calcium uniporter on mitochondrial fission in hippocampus cells ischemia/reperfusion injury. Biochem Biophys Res Commun 2015; 461(3): 537-42.
[http://dx.doi.org/10.1016/j.bbrc.2015.04.066] [PMID: 25911325]
[10]
Huang Q, Zhan L, Cao H, et al. Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways. Autophagy 2016; 12(6): 999-1014.
[http://dx.doi.org/10.1080/15548627.2016.1166318] [PMID: 27124102]
[11]
Marchi S, Corricelli M, Branchini A, et al. Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca2+ levels and tumor growth. EMBO J 2019; 38(2): e99435.
[http://dx.doi.org/10.15252/embj.201899435] [PMID: 30504268]
[12]
Giulietti M, Occhipinti G, Principato G, Piva F. Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development. Cell Oncol 2016; 39(4): 379-88.
[http://dx.doi.org/10.1007/s13402-016-0283-7] [PMID: 27240826]
[13]
Li X, Spelat R, Bartolini A, et al. Mechanisms of malignancy in glioblastoma cells are linked to MCU upregulation and higher intracellular calcium level. J Cell Sci 2020; jcs.237503.
[http://dx.doi.org/10.1242/jcs.237503]
[14]
Liu Y, Jin M, Wang Y, et al. MCU-induced mitochondrial calcium uptake promotes mitochondrial biogenesis and colorectal cancer growth. Signal Transduct Target Ther 2020; 5(1): 59.
[http://dx.doi.org/10.1038/s41392-020-0155-5] [PMID: 32371956]
[15]
Ren T, Zhang H, Wang J, et al. MCU-dependent mitochondrial Ca2+ inhibits NAD+/SIRT3/SOD2 pathway to promote ROS production and metastasis of HCC cells. Oncogene 2017; 36(42): 5897-909.
[http://dx.doi.org/10.1038/onc.2017.167] [PMID: 28650465]
[16]
Tosatto A, Sommaggio R, Kummerow C, et al. The mitochondrial calcium uniporter regulates breast cancer progression via HIF-1α. EMBO Mol Med 2016; 8(5): 569-85.
[http://dx.doi.org/10.15252/emmm.201606255] [PMID: 27138568]
[17]
Chen L, Sun Q, Zhou D, et al. HINT2 triggers mitochondrial Ca2+ influx by regulating the Mitochondrial Ca2+ Uniporter (MCU) complex and enhances gemcitabine apoptotic effect in pancreatic cancer. Cancer Lett 2017; 411: 106-16.
[http://dx.doi.org/10.1016/j.canlet.2017.09.020] [PMID: 28947137]
[18]
Wang X, Song X, Cheng G, et al. The regulatory mechanism and biological significance of mitochondrial calcium uniporter in the migration, invasion, angiogenesis and growth of gastric cancer. OncoTargets Ther 2020; 13: 11781-94.
[http://dx.doi.org/10.2147/OTT.S262049] [PMID: 33235465]
[19]
Arvizo RR, Moyano DF, Saha S, et al. Probing novel roles of the mitochondrial uniporter in ovarian cancer cells using nanoparticles. J Biol Chem 2013; 288(24): 17610-8.
[http://dx.doi.org/10.1074/jbc.M112.435206] [PMID: 23615904]
[20]
Cui C, Yang J, Fu L, Wang M, Wang X. Progress in understanding mitochondrial calcium uniporter complex-mediated calcium signalling: A potential target for cancer treatment. Br J Pharmacol 2019; 176(9): 1190-205.
[http://dx.doi.org/10.1111/bph.14632] [PMID: 30801705]
[21]
Mallilankaraman K, Doonan P, Cárdenas C, et al. MICU1 is an essential gatekeeper for MCU-mediated mitochondrial Ca(2+) uptake that regulates cell survival. Cell 2012; 151(3): 630-44.
[http://dx.doi.org/10.1016/j.cell.2012.10.011] [PMID: 23101630]
[22]
Cui C, Merritt R, Fu L, Pan Z. Targeting calcium signaling in cancer therapy. Acta Pharm Sin B 2017; 7(1): 3-17.
[http://dx.doi.org/10.1016/j.apsb.2016.11.001] [PMID: 28119804]
[23]
Stiles BL. PI-3-K and AKT: Onto the mitochondria. Adv Drug Deliv Rev 2009; 61(14): 1276-82.
[http://dx.doi.org/10.1016/j.addr.2009.07.017] [PMID: 19720099]
[24]
Saha S, Parte S, Roy P, Kakar SS. Ovarian cancer stem cells: Characterization and role in tumorigenesis. Adv Exp Med Biol 2021; 1330: 151-69.
[http://dx.doi.org/10.1007/978-3-030-73359-9_10] [PMID: 34339036]
[25]
Lu H, Chen I, Shimoda LA, et al. Chemotherapy-induced Ca2+ release stimulates breast cancer stem cell enrichment. Cell Rep 2017; 18(8): 1946-57.
[http://dx.doi.org/10.1016/j.celrep.2017.02.001] [PMID: 28228260]
[26]
Johnstone CN, Tu Y, Langenbach S, et al. Annexin A1 is required for efficient tumor initiation and cancer stem cell maintenance in a model of human breast cancer. Cancers 2021; 13(5): 1154.
[http://dx.doi.org/10.3390/cancers13051154] [PMID: 33800279]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy